Yahoo Finance

Daré Bioscience Announces Positive Efficacy Results from the DARE-HRT1 Phase 1 / 2 Study

SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced positive topline efficacy results from its Phase 1 / 2 ...
Nasdaq

More than 45 million women in the U.S. are approaching or in menopause

SAN DIEGO, July 27, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced the initiation of a Phase 1 clinical trial of DARE-HRT1.
Hosted on MSN

Daré Bioscience targets Q4 2025 launch for DARE to PLAY Sildenafil cream while advancing dual-path strategy

Johnson reiterated the targeted Q4 2025 launch for DARE to PLAY Sildenafil cream through a 503B outsourcing facility. She stated, "We remain on track to support a fourth quarter 2025 launch." ...
NBC4 Columbus

Daré Bioscience Announces Positive Pharmacokinetic (PK) Results from the DARE-HRT1 Phase 1 / 2 Study that Support the Potential of DARE-HRT1 as an Effective Hormone Therapy ...

Daré Plans to Advance DARE-HRT1 into Single Phase 3 Efficacy Trial for Treatment of Vasomotor Symptoms (VMS) due to Menopause DARE-HRT1 has the potential to be the first FDA-approved monthly ...
Yahoo Finance

Daré Bioscience Announces Positive Phase 1 Results for DARE-HRT1

SAN DIEGO, June 28, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced positive topline results from its Phase 1 clinical trial of ...
Nasdaq

Daré Bioscience Announces Positive Phase 1 Results for DARE-HRT1 | Nasdaq

The First Clinical Study Using the Novel Segmented Intravaginal Ring (IVR) Technology Validates its Potential to Provide a Versatile Convenient Drug Delivery Solution SAN DIEGO, June 28, 2021 (GLOBE ...